DSGN Stock Analysis: Buy, Sell, or Hold?
DSGN - Design Therapeutics, Inc. Common Stock
$11.23
0.22 (2.00%)
▲
5d:
+4.86%
30d:
+8.29%
90d:
+19.72%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When DSGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DSGN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DSGN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DSGN is currently trading at $11.23, which is considered extended relative to its 30-day fair value range of $10.10 to $10.79.
Technical Outlook: Technically, DSGN is in a strong uptrend. The price is approaching resistance at $11.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DSGN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.67 (+30.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DSGN is in a strong uptrend. The price is approaching resistance at $11.30. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: DSGN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.67 (+30.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$10.10 -
$10.79
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.6% below Wall St target ($14.67)
Fair Price Analysis
30-Day Fair Range
$10.10 -
$10.79
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$9.90
Resistance Level
$11.30
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.55
Wall Street Target
$14.67
(+30.6%)
Share & Embed Analysis
Last updated: April 02, 2026 10:26 PM ET
Data refreshes hourly during market hours. Next update: 11:26 PM
Data refreshes hourly during market hours. Next update: 11:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DSGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 66 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
